News › Clinical Practice, Industry News, Patient Care

Australia Survey Reveals Variation in Hyaluronidase Use in Aesthetic Practice

July 2, 2024
Vials of clear medication

New research suggests a need for guidelines around the storage and dosing for hyaluronidase (HYAL) when using hyaluronic acid (HA) fillers.

“Hyaluronic acids continue to be the fillers of choice worldwide and their popularity is growing,” the authors wrote in Aesthetic Surgery Journal. “Adverse events (AEs) are able to be resolved through the use of HYAL. However, routine HYAL use has been at issue due to perceived safety issues.”

The researchers noted that there are currently no established guidelines for HYAL use in aesthetic procedures, leading to inconsistent practices in storage, preparation, skin testing, and adverse event management. Their study utilized a 39-question survey about HYAL usage (completed by 264 healthcare practitioners: 244 from selected databases and 20 from a consensus panel). Responses from the database group were compared with those from the consensus panel.

Read more at Practical Dermatology >>

Review the study in full in Aesthetic Surgery Journal >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics’ Skinvive by Juvéderm Receives FDA Approval for the Improvement of Neck Appearance
    • Obagi Medical Announces FDA Approval of Obagi saypha ChIQ Injectable Hyaluronic Acid Gel
    • MedSafe Becomes Gold Vendor Affiliate with the American Med Spa Association
    • FDA Approves First New Sunscreen Ingredient in 20 Years
    • Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’ Highlighting Consumer Motivations and Expectations in Aesthetics